IL92167A - Preparation containing activin and / or inhibin - Google Patents

Preparation containing activin and / or inhibin

Info

Publication number
IL92167A
IL92167A IL9216789A IL9216789A IL92167A IL 92167 A IL92167 A IL 92167A IL 9216789 A IL9216789 A IL 9216789A IL 9216789 A IL9216789 A IL 9216789A IL 92167 A IL92167 A IL 92167A
Authority
IL
Israel
Prior art keywords
inhibin
chain
activin
globin
composition according
Prior art date
Application number
IL9216789A
Other languages
English (en)
Hebrew (he)
Other versions
IL92167A0 (en
Original Assignee
Perrine Susan P
Albers Norbert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perrine Susan P, Albers Norbert filed Critical Perrine Susan P
Publication of IL92167A0 publication Critical patent/IL92167A0/xx
Publication of IL92167A publication Critical patent/IL92167A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721Haemoglobin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL9216789A 1988-11-01 1989-10-31 Preparation containing activin and / or inhibin IL92167A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/266,421 US4997815A (en) 1988-11-01 1988-11-01 Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin

Publications (2)

Publication Number Publication Date
IL92167A0 IL92167A0 (en) 1990-07-12
IL92167A true IL92167A (en) 1994-07-31

Family

ID=23014518

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9216789A IL92167A (en) 1988-11-01 1989-10-31 Preparation containing activin and / or inhibin

Country Status (9)

Country Link
US (1) US4997815A (de)
EP (2) EP0367590B1 (de)
JP (1) JPH02256622A (de)
AT (1) ATE119396T1 (de)
CA (1) CA2001897A1 (de)
DE (1) DE68921546T2 (de)
IL (1) IL92167A (de)
MA (1) MA21667A1 (de)
PT (1) PT92174B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03173805A (ja) * 1989-09-11 1991-07-29 Ajinomoto Co Inc 卵分割促進剤
US5166190A (en) * 1990-01-08 1992-11-24 Genentech, Inc. Method for increasing fertility in males
US5102868A (en) * 1990-01-08 1992-04-07 Genentech, Inc. Method for inhibiting follicular maturation
US5942220A (en) * 1990-03-16 1999-08-24 Chiron Corporation Inhibitor of cytokine activity and applications thereof
EP0515494A1 (de) * 1990-02-15 1992-12-02 Chiron Corporation Verwendung von cytokinaktivitätsinhibitor
WO1992004913A1 (en) * 1990-09-13 1992-04-02 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US7910624B1 (en) 1995-03-03 2011-03-22 The Trustees Of Boston University Compositions for the treatment of blood disorders
WO1995005161A1 (en) * 1993-08-13 1995-02-23 Vitaphore Corporation Hydrogel-based microsphere drug delivery systems
US5487895A (en) * 1993-08-13 1996-01-30 Vitaphore Corporation Method for forming controlled release polymeric substrate
CA2174737C (en) * 1993-10-29 2008-04-22 Douglas V. Faller Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
US5700640A (en) * 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5545616A (en) * 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
AU3889197A (en) 1996-07-26 1998-02-20 Douglas V Faller Compositions comprising an inducing agent and an anti-viral agent for the treat ment of blood, viral and cellular disorders
AUPO638897A0 (en) * 1997-04-23 1997-05-22 Monash University Modulation of cell growth and methods relating thereto
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
WO1999040883A2 (en) * 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
US20060003446A1 (en) * 2002-05-17 2006-01-05 Gordon Keller Mesoderm and definitive endoderm cell populations
AU2012203441B2 (en) * 2002-05-17 2015-01-29 Mount Sinai School Of Medicine Of New York University Mesoderm and definitive endoderm cell populations
AU2003304106C1 (en) * 2002-05-17 2010-10-28 Mount Sinai School Of Medicine Of New York University Mesoderm and definitive endoderm cell populations
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US20060040868A1 (en) * 2004-08-10 2006-02-23 Bowen Richard L Methods for treating premature infants
US7642275B2 (en) * 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1896436A2 (de) * 2005-05-11 2008-03-12 Takeda San Diego, Inc. Inhibitoren der histondeacetylase
CN101263121A (zh) * 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
EP1976835A2 (de) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histondeacetylase-inhibitoren
US8874380B2 (en) 2010-12-09 2014-10-28 Rutgers, The State University Of New Jersey Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
EP2509418A4 (de) 2009-12-08 2013-03-20 Hemaquest Pharmaceuticals Inc Verfahren und niedrigdosierungspläne zur behandlung von erythrozytendysfunktion
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2016064815A1 (en) * 2014-10-20 2016-04-28 Massachusetts Institute Of Technology Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
AU2020283590A1 (en) 2019-05-31 2022-01-20 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors
MX2024004801A (es) 2021-10-19 2024-06-28 Akirabio Inc Composiciones que comprenden análogos de 2'- desoxicitidina, y uso de las mismas para el tratamiento de anemia de células falciformes, talasemia y cánceres.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0730114B2 (ja) * 1985-04-03 1995-04-05 正雄 五十嵐 インヒビン
JPH0637520B2 (ja) * 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
US4740587A (en) * 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
NZ217727A (en) * 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US4822821A (en) * 1986-10-10 1989-04-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
AU610858B2 (en) * 1987-01-29 1991-05-30 Inhibin Pty Limited Isolation of single chain proteins with fsh suppressing activity from follicular fluid
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5032507A (en) * 1987-11-13 1991-07-16 The Salk Institute For Biological Studies Potentiation of erythropoiesis

Also Published As

Publication number Publication date
US4997815A (en) 1991-03-05
PT92174A (pt) 1990-05-31
DE68921546D1 (de) 1995-04-13
JPH02256622A (ja) 1990-10-17
PT92174B (pt) 1995-09-12
EP0367590A2 (de) 1990-05-09
EP0367590B1 (de) 1995-03-08
CA2001897A1 (en) 1990-05-01
IL92167A0 (en) 1990-07-12
EP0367590A3 (de) 1992-01-02
MA21667A1 (fr) 1990-07-01
ATE119396T1 (de) 1995-03-15
EP0617966A1 (de) 1994-10-05
DE68921546T2 (de) 1995-07-06

Similar Documents

Publication Publication Date Title
US4997815A (en) Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin
US5216004A (en) Method for preventing malaria
EP0548276A4 (en) Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5646113A (en) Treatment of partial growth hormone insensitivity syndrome
US5126324A (en) Method of enhancing growth in patients using combination therapy
AU655059B2 (en) Method of stimulating immune response
US4699897A (en) Biologically active peptides structurally related to regions within growth hormones
US5681814A (en) Formulated IGF-I Composition
US20090088380A1 (en) Ghrh analogs and therapeutic uses thereof
CA2185998C (en) The combination of growth hormone and insulin-like growth factor, for treating congestive heart failure
AU2003229222B2 (en) GRF analog compositions and their use
US5824642A (en) Treatment of partial growth hormone insensitivity syndrome
US6207640B1 (en) Treatment of partial growth hormone insensitivity syndrome
Fatouros et al. Alterations in body weight, breaking strength, and wound healing in Wistar rats treated pre-and postoperatively with erythropoietin or granulocyte macrophage–colony stimulating factor: Evidence of a previously unknown anabolic effect of erythropoietin?
JPH08502969A (ja) 肥満の予防または治療方法
US20210008164A1 (en) Erythropoietin for Gastrointestinal Dysfunction
Cotes Erythropoietin: the developing story
US5317012A (en) Human growth hormone induced improvement in depressed T4/T8 ratio
WO1999049894A1 (en) Antagonists to growth arrest specific gene 6 to treat insulin-resistant disorders
Baumann Molecular heterogeneity of circulating growth hormone in acromegaly
MXPA98009140A (en) Treatment of the partial insensitivity syndrome to the growth hormone
JPH03505088A (ja) ホルモン類の作用
MXPA96004802A (en) Treatment of cardiac failure congest

Legal Events

Date Code Title Description
RH Patent void